Back to results

Phase II Study of Tailored Adjuvant Therapy in Pole-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer (Rainbo Blue & Taper)

Objective

Estimate the rate of pelvic recurrence at 3 years in patients who are treated with a de-escalated adjuvant treatment directed by tumour molecular status.

Protocol #

NRG-GY032

Trial Phase:

Phase II

Principal Investigator:

Fields, Emma

Cancer Type
  • Corpus Uteri
Study Site
  • New Kent ED
  • Short Pump Pavilion (formerly known as N.O.W. Center)
  • Stony Point
  • Tappahannock
  • Tappahannock - VCU Study Site
  • Virginia Commonwealth University

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Treatment
  • Research Study Team Melanie Hamilton, RN
    Phone: +1 804-628-7130
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: